| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01a96e8bbea00eeaa0b50c2a0c000dba |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4458
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4458 |
| filingDate |
2013-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4659f5345746d709aa5b6ec33c412428
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cea09c8a376033a2277b3fa4d913b6c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0fbc06ef1898ec86bc456bc7239096e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d886174b2068aadf9cbc50b5823e9a92 |
| publicationDate |
2013-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013289061-A1 |
| titleOfInvention |
Methods and compositions to prevent addiction |
| abstract |
Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject comprising, administering a therapeutic amount of the neurological stimulant and administering an antagonist of the kappa opioid receptor, to thereby reduce or prevent the development of aversion to the CNS stimulant in the subject. Also disclosed is a method of reducing or preventing the development of addiction to a CNS stimulant in a subject, comprising, administering the CNS stimulant and administering a mu opioid receptor antagonist to thereby reduce or prevent the development of addiction to the CNS stimulant in the subject. Also disclosed are pharmaceutical compositions comprising a central nervous system stimulant and an opioid receptor antagonist. Examples of central nervous system stimulants (such as methylphenidate) and opioid receptor antagonists (such as naltrexone) are provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2679661-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9725457-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020036970-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11046692-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014255308-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9545400-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10150775-B2 |
| priorityDate |
2009-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |